Subscribe
shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
18 November 2020AmericasRory O'Neill

GSK, Amgen want SCOTUS to protect genus claims

Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme (MSD) in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Americas
SCOTUS weighs future of assignor estoppel
11 January 2021   The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.
Americas
Fed Circuit affirms GSK $107m patent loss
20 November 2020   The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Americas
SCOTUS weighs future of assignor estoppel
11 January 2021   The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.
Americas
Fed Circuit affirms GSK $107m patent loss
20 November 2020   The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.

More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Americas
SCOTUS weighs future of assignor estoppel
11 January 2021   The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.
Americas
Fed Circuit affirms GSK $107m patent loss
20 November 2020   The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?